Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
Benjamin A. Fisher, Xavier Mariette, Athena Papas, TWINSS Study Group, Thomas Grader-Beck, Hendrika Bootsma, Wan Fai Ng, P. L.A. van Daele, Stephanie Finzel, Ghaith Noaiseh, Sergio Elgueta, Josef Hermann, Sara S. McCoy, Esen Akpek, Arthur Bookman, Monika Sopala, Michela Montecchi-Palmer, Wen Lin Luo, Cornelia Scheurer, Wolfgang Hueber*
Research output: Contribution to journal › Article › Academic › peer-review
15Citations
(Scopus)
19Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study'. Together they form a unique fingerprint.